search

The latest round of the Horizon 2020 SME Instrument has seen the successful funding of a Luxembourgish SME, Braingineering Technologies, which has been positively evaluated for a Phase 1 project.

SMEs (Small and Medium-sized Enterprises) that are EU-based or established in a country associated with Horizon 2020 can get EU funding and support for “breakthrough innovation projects with a market-creating potential” under the revamped SME instrument, which has been rolled out as part of the European Innovation Council (EIC) pilot. The SME Instrument supports high-risk, high-potential SMEs to develop and bring to market new products, services and business models that could drive economic growth.

The SME Instrument, which from 2018 has become an integral part of the European Innovation Council (EIC) Pilot, is an extremely competitive funding instrument, with an overall success rate of 8.4% for Phase 1 and 5.5% for Phase 2. Phase 1 aims at supporting the company in getting a grip on the R&D, technical feasibility and commercial potential of a ground-breaking, innovative idea and developing it into a credible business plan for scaling it up. Projects receive a lump sum of € 50,000 and last around 6 months. Phase 2 helps the companies in developing their business concept further into a market-ready product, service or process aligned with the growth strategy; projects, lasting 12 to 24 months, are funded between € 0.5 and € 2.5 million.

Braingineering Technologies (BTech), the “brainchild” of Professor Jens Schwamborn, is a young and innovative spin-off company from the Luxembourg Centre of Systems Biomedicine (LCSB), an interdisciplinary centre of the University of Luxembourg. BTech cultures human induced pluripotent stem cells (iPSCs) in a specific environment, thereby stimulating the development of so-called mini-brain organoids. These 3D structures, unlike traditional cell culture models, largely mimic the organisation and function of a real brain. Importantly, because these mini-brains can be cultured in arrays on microfluidic plates, they can be used for drug screening in a more cost and time efficient manner than would be possible with animal testing.

Furthermore, as iPSCs can nowadays be easily derived directly from a small biopsy (e.g. from Parkinson’s patients), the respective mini-brains carry exactly the same mutations as the patient, thus allowing for the development of truly personalised medicine. BTech uses their proprietary model to do pre-clinical drug testing and toxicology studies for pharmaceutical companies to identify new treatments for Parkinson’s disease. The support and coaching that BTech will receive through the first phase of the SME instrument will contribute to their consolidation and business development in the biotech sector.

Read more

Horizon Europe: 7 best tips to get started

16-06-2021

The Horizon Europe work programmes for 2021-2022 have just been published. This marks the start of seven bustling years of European research and innovation. The programme offers attractive opportunities for funding, international partnerships and valuable project results, but the process to get there can be complex. Luxinnovation’s EU funding experts offer their best advice for how to start successfully.
Read more

Horizon 2020 Green Deal call: €3 million to Luxembourg for green transition

16-06-2021

The recent Horizon 2020 Green Deal call for proposals attracted an exceptionally high number of proposals. The preliminary results show that Luxembourg applicants stood their ground well in the competition and will receive EU funding of almost €3 million for project related to key areas of the green transition.
Read more

Matchmaking events for Horizon Europe

14-06-2021

Several matchmaking events are organised around the different thematics of Horizon Europe. A matchmaking event allows participants to find like-minded participants to discuss potential collaboration and future opportunities. They are a great way to find partners for Horizon Europe projects.
Read more

MSCA application deadline postponed

10-06-2021

The adoption of the Horizon Europe work programmes is facing some delays due to still ongoing negotiations. The call application deadlines are thus postponed for some work programmes. This postponing of the deadline affects the Marie Skłodowska-Curie Actions (MSCA) programme, in particular for two specific actions: the MSCA Doctoral Networks and the MSCA Postdoctoral Fellowships.
Read more

European Parliament adopts Horizon Europe programme

29-04-2021

The 2021-2027 research and innovation programme will help the EU’s health systems prepare for future pandemics, and its industry to decarbonise, digitalise and innovate.
Read more

Resources all news

Fermer